Author Archive: Jeremy Parkinson
Oh, SNAP
It only took three days as a public company to do so, but 100% of the public buyers of SNAP have now lost money. (And if you mention the $17 offer price, you have no clue what you’re talking about). The stock’sprice and the company’s user base will have something in common soon – – both […]
3 Stocks To Watch That Report Earnings Tomorrow – Tuesday, March 7
Urban Outfitters (URBN): About a month ago, Urban Outfitters reported preliminary sales results for the fourth quarter and full year fiscal 2017. In the three months ending January 31, net sales increased 2% from a year earlier to $1.03 billion. Comparable retail sales, including booming direct to consumer channels, came in flat largely on lower retailer […]
Bond Market Dancing To A Different Tune Than Equities
Whenever we see trends in the market we immediately look for confirming data points. With the impressive rise in equity markets since the election, we look at the bond market to see if there is agreement on all this bullishness. There isn’t. “The bond market is taking a totally different view from the equity market. […]
High Debt & Low Revenue Growth Didn’t Cause A Crash
The stock market was down Monday. The S&P 500 is down about 1% from its all-time high. Anytime the stock market has been down since the election, it’s bigger news than it normally would be because it’s been in almost a straight line higher. It is difficult to remember what a normal market is like […]
Invest Like Warren Buffett With These 5 Excellent Stocks
Any number of financial analysts, experts and asset managers would be eager to guide you about how to go about investing the Warren Buffett way. Yet, few have managed to match the success of this plain talking veteran who has consistently outperformed most other investors over an extended period. Buffett is always market-relevant, but there […]
Monday’s Biotech Insights: Concert Pharmaceuticals Inc (CNCE), TG Therapeutics Inc (TGTX)
Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares skyrocketed today following the news that Vertex Pharmaceuticals (NASDAQ:VRTX) will acquire Concert’s deuterated Kalydeco variant, CTP-656, for $160 million upfront with up to $90 million in milestones. The drug is currently in phase 2 studies in monotherapy, with results expected in the fourth-quarter of this year. J.P. Morgan analyst Cory Kasimov commented, “We believe this […]
Beware The German “Hump”
I’ve talked tirelessly (well, I haven’t gotten tired of it, maybe you have) about the extent to which markets are or aren’t correctly pricing event risk around Europe’s trio of electoral trials by fire. For obvious reasons, the French elections have gotten the most attention. That’s probably justified given the fact that there’s a non-negligible chance that France accidentally […]
Stocks Post 35-Year Breakout
Stocks Inside Box Since 1982 The Value Line Geometric Index is a broad, equally-weighted index that can be used to monitor the health of the stock market beyond the capitalization-weighted S&P 500. As shown in the monthly chart below, the orange box acted as both support (green arrows) and resistance (red arrows) several times between […]
‘Fake’ New York Times Gets Boost From The Donald
President Trump has demonstrated extraordinary hostility towards the news media, calling it the “opposition party” and refusing to allow journalists from The New York Times (NYSE:NYT) in particular to attend a White House briefing. However, it appears his actions are benefiting the NYT stock price. At least, we see a correlation with the constant slander […]
Will AUD Sink To 75 Cents?
The Reserve Bank of Australia has a monetary policy meeting this evening . While the central bank is widely expected to keep interest rates unchanged, the Australian dollar is the best performing currency this year and its strength could worry the RBA. Since Jan 1, AUD is up more than 5.5% versus GBP, more than […]
